Concepedia

Author

Anna Świeboda-Sadlej

Medical University of Warsaw

Also Known As

A Swieboda-Sadlej, A. Swieboda-Sadlej, A. Świeboda-Sadlej, Anna Swieboda-Sadlej, Anna Świeboda-Sadlej

43

Publications

623

Citations

9

H-Index

17

Concepts

All Affiliations

Medical University of WarsawKU LeuvenAmgen (United States)Pfizer (United States)Central Clinical Hospital
AŚ

About

Anna Świeboda-Sadlej is an author at Medical University of Warsaw specializing in oncology, cancer therapeutics, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

310

2

Pathology

4

4

147

3

Pharmacology

4

4

147

4

Health Sciences

2

2

200

5

Immunology

1

1

37

Anna Świeboda-Sadlej

×

8

Publications

583

Citations

8

H-Index

YearCitations

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

Charles S. Fuchs, Sérgio Jobim Azevedo, Takuji Okusaka,

Annals of Oncology

2015

163

Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial

Alfredo Carrato, Anna Świeboda-Sadlej, Marzanna Staszewska-Skurczyńska,

Journal of Clinical Oncology

2013

132

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type <i>KRAS</i> Metastatic Colorectal Cancer

Eric Van Cutsem, Cathy Eng, Elżbieta Nowara,

Clinical Cancer Research

2014

107

Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer

Martin Eatock, Niall C. Tebbutt, Carolyn Bampton,

Annals of Oncology

2012

64

A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) <i>KRAS</i> metastatic colorectal cancer (mCRC): Primary and biomarker analyses.

Cathy Eng, Eric Van Cutsem, Elżbieta Nowara,

Journal of Clinical Oncology

2011

37

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer

Chris Twelves, Ewa Chmielowska, Libor Havel,

Annals of Oncology

2013

34

Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study

Johanna C. Bendell, Christophe Tournigand, Anna Świeboda-Sadlej,

Clinical Colorectal Cancer

2013

31

Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC).

Johanna C. Bendell, C. Tournigand, Martyna Bednarczyk,

Journal of Clinical Oncology

2011

15

Page 1